Thematics Asset Management Has $3.46 Million Stock Position in CVS Health Co. (NYSE:CVS)

Thematics Asset Management raised its position in CVS Health Co. (NYSE:CVS - Free Report) by 34.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 77,029 shares of the pharmacy operator's stock after acquiring an additional 19,653 shares during the period. Thematics Asset Management's holdings in CVS Health were worth $3,458,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the business. Dodge & Cox grew its position in CVS Health by 11.2% in the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after purchasing an additional 7,075,209 shares in the last quarter. Capital World Investors increased its position in shares of CVS Health by 26.6% in the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after acquiring an additional 12,819,148 shares during the last quarter. Geode Capital Management LLC raised its holdings in CVS Health by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 27,051,540 shares of the pharmacy operator's stock worth $1,211,582,000 after acquiring an additional 689,867 shares in the last quarter. Capital International Investors boosted its position in CVS Health by 4.8% during the fourth quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after purchasing an additional 1,212,126 shares during the last quarter. Finally, Pzena Investment Management LLC grew its stake in CVS Health by 49.3% in the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock valued at $880,319,000 after purchasing an additional 6,475,271 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

Analyst Ratings Changes

CVS has been the subject of a number of analyst reports. Evercore ISI lifted their price objective on shares of CVS Health from $60.00 to $65.00 and gave the company an "outperform" rating in a research report on Monday, January 27th. Morgan Stanley restated an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Truist Financial lifted their price objective on shares of CVS Health from $76.00 to $82.00 and gave the stock a "buy" rating in a research report on Friday, April 11th. Cantor Fitzgerald upgraded shares of CVS Health from a "neutral" rating to an "overweight" rating in a research note on Wednesday, February 12th. Finally, Robert W. Baird increased their price target on shares of CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a report on Tuesday, April 15th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $71.83.

Insider Activity at CVS Health

In other CVS Health news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael F. Mahoney purchased 30,000 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. 1.22% of the stock is currently owned by insiders.

CVS Health Price Performance

Shares of CVS Health stock traded up $0.29 on Thursday, reaching $65.86. 7,010,414 shares of the stock were exchanged, compared to its average volume of 11,822,876. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The firm has a market cap of $83.04 billion, a PE ratio of 17.99, a P/E/G ratio of 0.98 and a beta of 0.57. The firm's 50 day moving average is $66.48 and its 200-day moving average is $58.82. CVS Health Co. has a one year low of $43.56 and a one year high of $71.45.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be issued a $0.665 dividend. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.04%. CVS Health's dividend payout ratio (DPR) is currently 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.